- Home
- FBRX vs PSBD Comparison
FBRX vs PSBD Comparison
Compare FBRX & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$24.09
Company Overview
Basic Information| Metric | FBRX | PSBD |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 386.6M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FBRX | PSBD |
|---|---|---|
| Price | $24.09 | $9.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $67.00 | $12.50 |
| AVG Volume (30 Days) | ★ 196.5K | 83.1K |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 16.79% |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ 1.66 |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.89 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.91 | $9.50 |
| 52 Week High | $35.62 | $14.96 |
Technical Indicators
Market Signals| Indicator | FBRX | PSBD |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 31.84 |
| Support Level | $21.94 | N/A |
| Resistance Level | $32.40 | $12.39 |
| Average True Range (ATR) | 2.65 | 0.40 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 26.15 | 15.97 |
Price Performance
Historical Comparison FBRX
PSBD
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.